Pharmaceuticals, Biotechnology and Life Sciences
FARMINGTON, Conn.–(BUSINESS WIRE)–Azitra Inc., a clinical-stage medical dermatology company addressing serious skin conditions by harnessing the microbiome, today announced that…
Azitra will be presenting results from the joint researchshowing the successful genetic engineering of the common skin bacterium, Staphylococcusepidermidis, to produce high levels of functional LEKTI protein, aprotease inhibitor involved in regulating the rate of skin loss.